Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
as-miR-937-expressing mesenchymal stem cells
- Development stage
- Preclinical
- Lead developer
- Zhen Liu
- Modality
- Cell Therapies, Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
as-miR-937-expressing mesenchymal stem cells is a preclinical, research-stage gene-modified cell therapy consisting of bone marrow-derived mesenchymal stem cells (MSCs) engineered via adeno-associated virus (AAV)-mediated transduction to overexpress the antisense of microRNA-937 (as-miR-937). This modification is designed to inhibit endogenous miR-937, which naturally suppresses the translation of the neuronal transcription factor Brn-4 (POU3F4). By downregulating miR-937, the therapy upregulates Brn-4 protein levels, promoting neuronal development and neuroprotection. In murine models of Alzheimer's disease, transplantation of these modified MSCs has demonstrated the ability to reduce amyloid-beta (Aβ) plaque deposition, increase brain-derived neurotrophic factor (BDNF) levels, and improve cognitive and behavioral performance. The therapy was described in a 2015 study by academic researchers and is not currently associated with a commercial developer.
- Other names
- as-miR-937 MSCsas-miR937 MSCsas-miR 937 MSCsantisense-miR-937-expressing mesenchymal stem cellsantisense-miR937-expressing mesenchymal stem cellsantisense-miR 937-expressing mesenchymal stem cellsmiR-937-modified MSCsmiR937-modified MSCsmiR 937-modified MSCs
Beyond the preview
Go deeper on as-miR-937-expressing mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on as-miR-937-expressing mesenchymal stem cells.